Table 2 ICU-specific antimicrobial consumption in DDDs, KAMC-R,2012–2015
From: Antimicrobial consumption in five adult intensive care units: a 33-month surveillance study
| Â | Medical/ surgical | Neuro-surgical | Burn | Cardio-thoracic | Step-down | Total |
|---|---|---|---|---|---|---|
Number of DDDs | ||||||
 Aminoglycosides | 449.0 | 161.4 | 84.3 | 24.6 | 350.2 | 1069.5 |
 Carbapenems | 6890.1 | 1886.4 | 1102.5 | 772.0 | 3198.6 | 13,849.5 |
 Cephalosporins | 1278.8 | 610.2 | 158.3 | 52.2 | 476.7 | 2576.1 |
 Fluoroquinolones | 1822.0 | 635.0 | 376.5 | 395.4 | 1306.8 | 4535.6 |
 Piperacillin/Tazobactam | 3044.2 | 1528.0 | 605.8 | 929.9 | 1162.4 | 7270.2 |
 Vancomycin | 2362.2 | 1030.5 | 513.4 | 388.0 | 1018.1 | 5312.2 |
 Tigecycline | 562.5 | 8.5 | 324.0 | 52.5 | 308.0 | 1255.5 |
 Colistin | 305.6 | 93.5 | 138.1 | 21.4 | 179.8 | 738.3 |
 Caspofungin | 2572.7 | 195.4 | 179.0 | 187.4 | 991.0 | 4125.5 |
 Amphotericin B | 1694.9 | 137.1 | 150.9 | 0.0 | 1254.7 | 3237.6 |
 Total | 20,981.9 | 6285.9 | 3632.7 | 2823.4 | 10,246.3 | 43,970.1 |
Denominator | ||||||
 Patient days | 19,105 | 7288 | 6759 | 7105 | 13,859 | 54,116 |
 Admissions | 1620 | 786 | 391 | 1499 | 623 | 4919 |
 Average length of stay | 11.8 | 9.3 | 17.3 | 4.7 | 22.2 | 11.0 |
Rates per 1000 patient-days | ||||||
 Aminoglycosides | 23.5 | 22.1 | 12.5 | 3.5 | 25.3 | 19.8 |
 Carbapenems | 360.6 | 258.8 | 163.1 | 108.7 | 230.8 | 255.9 |
 Cephalosporins | 66.9 | 83.7 | 23.4 | 7.4 | 34.4 | 47.6 |
 Fluoroquinolones | 95.4 | 87.1 | 55.7 | 55.7 | 94.3 | 83.8 |
 Piperacillin/Tazobactam | 159.3 | 209.7 | 89.6 | 130.9 | 83.9 | 134.3 |
 Vancomycin | 123.6 | 141.4 | 76.0 | 54.6 | 73.5 | 98.2 |
 Tigecycline | 29.4 | 1.2 | 47.9 | 7.4 | 22.2 | 23.2 |
 Colistin | 16.0 | 12.8 | 20.4 | 3.0 | 13.0 | 13.6 |
 Caspofungin | 134.7 | 26.8 | 26.5 | 26.4 | 71.5 | 76.2 |
 Amphotericin B | 88.7 | 18.8 | 22.3 | 0.0 | 90.5 | 59.8 |
 Total | 1098.2 | 862.5 | 537.5 | 397.4 | 739.3 | 812.5 |